Full Text
Cost-Effectiveness of Ibrutinib and Rituximab for the Relapsed or Refractory Chronic Lymphocytic Leukemia in China

Abstract

Authors

F Yang A Kumar S Rojanasarot JC Schommer R Shao

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×